Immune checkpoint targeted drug conjugate therapies: Bridging preclinical and clinical innovation for solid tumor...

Area of Science:

• Oncology
• Immunotherapy
• Drug Development

Background:

• Solid tumors present significant therapeutic challenges due to complex biology and resistance to standard treatments.
• Immune checkpoint inhibitors (ICIs) have advanced cancer therapy but face limitations like low response rates and toxicities.
• Immune checkpoint targeting drug conjugates (IDCs) represent an innovative strategy to enhance efficacy and selectivity.

Purpose of the Study:

• To review the design, mechanism, and progress of IDCs in solid tumor treatment.
• To highlight key targets, including PD-L1/PD-1, TIGIT, CTLA-4, and LAG-3.
• To examine translational challenges and emerging innovations in IDC development.

Main Methods:

• Review of current clinical and preclinical data on IDCs.
• Analysis of design principles and operational mechanisms of IDCs.
• Examination of targeted delivery using monoclonal antibodies or engineered scaffolds with effector molecules.

Main Results:

• IDCs combine checkpoint blockade with targeted cytotoxic or immunomodulatory payloads.
• They aim to improve tumor selectivity, enhance T-cell activity, and induce direct tumor cell death.
• Key targets include PD-L1/PD-1, TIGIT, CTLA-4, and LAG-3, with ongoing research into bispecific formats and combinations.

Conclusions:

• IDCs show promise as a next-generation therapy for solid tumors.
• They have the potential to overcome resistance and improve durable therapeutic outcomes.
• Addressing safety, resistance, and manufacturing complexities is crucial for clinical translation.